Preparing healthcare companies for success
in the value-based economy

Harvard Pilgrim & Illumina
Risk Sharing Agreement

more info >



Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.

more >


Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.

more >

News and Events

Payer Perspective on Reimbursement of One-Time High-Cost Durable Therapies

by Jane Barlow

The reimbursement of emerging durable and potentially curative cell and gene therapies challenge U.S. payers due to their high upfront costs. In addition, the lack of long-term clinical durability data amplifies uncertainties which complicate payer coverage and reimbursement determinations. These cell and gene therapy characteristics could negatively impact patient access and ultimately, future developer innovation.  The Financing and Reimbursement of Cures in the U.S. (FoCUS) project was launched in 2016 by MIT with the objective of elucidating the challenges and financial impact created by durable/potentially curative therapies and providing implementable models to manage the financial impact on the U.S. healthcare system.

January 9, 2020

read full article >

Panel: Drug Pricing and Value Based Reimbursement

Jeff Berkowitz

Real Endpoints

Biotech’s CEOs at the annual Laguna meeting next week will be talking — as are their investors -- about how to pay for innovation, particularly as the industry runs from major chronic disease to narrow orphan indications where pricing has been relatively protected. Real Endpoints’ CEO Jeff Berkowitz will be on a panel defining the increasing challenges of this approach, particularly given how competitive even the narrowest orphan conditions have become, and how companies must adapt to meet them.

October 13, 2019 -
October 15, 2019

Laguna Beach, CA

Real Endpoints: Research supports expanding insurance coverage of non-invasive prenatal testing

by University of Colorado

Research conducted by the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences provides evidence to support expansion of insurance plan coverage of noninvasive prenatal testing (NIPT), to women under the age of 35. It represents a first-of-its-kind published analysis of results from a risk-sharing agreement between biotechnology company Illumina, Inc. and insurer Harvard Pilgrim Health Care, conducting the research in partnership with advisory firm Real Endpoints to evaluate the impacts of the agreement.

October 8, 2019


read full press release >

Recent Insights

view archive >

November 14, 2019

Market Access 2020: Understanding US Payer Expectations

Consolidation on the payer side is changing the dynamics of success in health care.  Principals at Real Endpoints LLC examine

read full insight article >

June 11, 2019

Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?

Access to new gene therapies may be impacted by payer ability to absorb the cost of coverage. Payers are open to innovative financing models that improve financial predictability and reward clinical performance.

read full insight article >